Opdivo Could Extend Life of Mesothelioma Victims: Study
Opdivo may help extend the life of mesothelioma patients, according to the findings of a new study.
Opdivo may help extend the life of mesothelioma patients, according to the findings of a new study.
The FDA has approved the use of a drug combination of Opdivo and Yervoy as a first-line treatment for mesothelioma.
Most cancer drugs fast-tracked through a special FDA program do not appear to actually help cancer patients live longer, according to the findings of a new study.
After halting clinical trials involving the cancer drug Keytruda for treatment of multiple myeloma, the FDA has expanded the suspension to trials involving Opdivo, a similar medication.
A new study warns that combination cancer therapy involving Opdivo and Yervoy may often be too toxic for patients, resulting in hospitalizations and emergency room visits due to immune system…
The cancer drugs Opdivo and Yervoy may slow the progression of mesothelioma, according to the findings of a new study.
An investigative report finds that cancer drugs and treatments are often oversold, exaggerating their effectiveness.
Two Bristol-Myers Squibb cancer drugs, Opdivo and Yervoy, may be linked to fatal heart problems when used in combination, according to the findings of a new study.
The cancer drugs Yervoy and Opdivo could increase the risk of arthritis, according to the findings of a new case study.